OCR, your partner for comparative medicine studies
OCR is specialized in the design of clinical studies of pets with naturally occurring pathologies
for efficacy assessment of drug candidates and medical devices for Human Health.
OCR and ImaBiotech initiate a strategic partnership to provide in situ drug efficacy and target exposure services in Pets with naturally occuring tumors.
OCR together with ImmunXperts and Rarecells win k€520 funding in Eureka Eurostars program to initiate €1,3m “ICOM” platform for preclinical and clinical human cancer drug evaluation in pet dog’s model.
OCR the company revolutionising the selection of effective drug candidates for cancer, raises €1.25m from Newfund, NFA and the management team in order to accelerate its growth.
OCR strengthens veterinary and R&D expertise to respond to the needs of the pharmaceutical industry.
Stay connected to OCR, subscribe to our Newsletter !
Contact Us
WE WOULD BE DELIGHTED TO HEAR FROM YOU !
OCR FRANCE
Fanny LEPRETRE
contact@oncovet-clinical-research.com
Parc Eurasanté – Lille Métropole
80 rue du Dr Yersin, 59120 Loos
Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site. Si vous continuez à utiliser ce dernier, nous considérerons que vous acceptez l'utilisation des cookies.Ok